Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

471P - Chemotherapy in advanced thymic malignancies

Date

23 Nov 2019

Session

Poster display session

Topics

Tumour Site

Thymoma and Thymic Cancer

Presenters

Ankur Varshney

Citation

Annals of Oncology (2019) 30 (suppl_9): ix153-ix156. 10.1093/annonc/mdz436

Authors

A.N. Varshney1, I. Vanidassane2, D. Ramavth2, P.S. Malik3, S. Khurana4, V. Garg5, S.P. Vadlamani2, K. Kalra5, S. Gunasekar6, S. Kumar7, S. Sethi8, M. Yadav8, S. Pathy9, D. Jain10

Author affiliations

  • 1 Medical Oncology, AIIMS - All India Institute of Medical Sciences, 201301 - NOIDA/IN
  • 2 Medical Oncology, AIIMS - All India Institute of Medical Sciences, 110029 - NEW DELHI/IN
  • 3 Medical Oncology, B.R. Ambedkar Institute Rotary Cancer Hospital (AIMS), 110029 - New Delhi/IN
  • 4 Medical Oncology, AIIMS - All India Institute of Medical Sciences, 110029 - Delhi/IN
  • 5 Medical Oncology, AIIMS - All India Institute of Medical Sciences, 110029 - New Delhi/IN
  • 6 Surgical Oncology, Institute Rotary Cancer Hospital, 110029 - New Delhi/IN
  • 7 Surgical Oncology, All India Institute of Medical Sciences, 1110029 - New Delhi/IN
  • 8 Radiodiagnosis, AIIMS - All India Institute of Medical Sciences, 110029 - NEW DELHI/IN
  • 9 Radiation Oncology, All India Institute of Medical Sciences, 110029 - New Delhi/IN
  • 10 Pathology, AIIMS - All India Institute of Medical Sciences, 110029 - NEW DELHI/IN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 471P

Background

Despite being a rare disease entity, Thymoma and Thymic carcinomas represent the most common cause of anterior mediastinal mass. Clinical course is widely varied from an indolent course to florid metastatic disease with paraneoplastic manifestation. Treatment guidelines are based on small phase 2 studies. Data of chemotherapy in advanced thymoma is limited.

Methods

It is a retrospective study of advanced thymic epithelial tumors treated with chemotherapy over a period of 7 years (2011 -2017). All patients with unresectable /metastatic thymic tumours and who have received chemotherapy as were included in the study. Independent review of radiology images and histopathology slides were performed.

Results

There were 55 cases registered with thymic malignancy and 32 cases were analyzed for present study. Among them 27 cases were thymoma, 3 were thymic carcinoma and 2 were thymic NET. The median age was 39 years (22 65 years). Male: female ratio was 3: 1. The median duration of symptoms was 5.9 months (0-36 months). Twelve cases (38%) had features of superior vena cava obstruction at presentation. The mean size of mediastinal mass was 8.9 + 3.26 (range 2-15 cm). More than half of the cases (56%) showed calcification. Mediastinal lymph nodes were seen in 14 patients (46%). There was pleural involvement in 14 patients (73%) and pericardial involvement in 13 cases (43%). Pleural effusion was seen in 17(53%). Only 5 cases had stage III, 18 had stage Iva and 9 had stage IVb disease. The most common histological subtype as per WHO classification was B1 in 11 patients (34%) followed by B3 in 9 patients (28%) in our cohort. Out of 32 cases 3 have had upfront R2 resection. Post chemotherapy, one case attained CR, 10 had PR, 13 had SD and 3 had PD. 6 cases underwent surgery post induction therapy. 3 had R1 resection and 3 had R2 resection. Cisplatin, doxorubicin and cyclophosphamide (CAP) remains first choice for chemotherapy in 81% patients followed by paclitaxel-carboplatin in 12.5%. Radiation therapy was given to 13 patients. After a median follow up of 24.86 months, median PFS is 16.1 months and median OS was not reached.

Conclusions

Thymic malignancies are a heterogeneous group of disorders. Multi-modality treatment including chemotherapy is an effective and feasible treatment for advanced thymoma.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

All authors are equally responsible. Institute ethics committee has given the clearance.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.